As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
JEEN’s portfolio includes a diverse range of specialized active ingredients, botanical extracts, and complexes serving functional applications for skin and hair care
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
This has further strengthened its manufacturing presence in the United States of America
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
